By Model System
LIDE’s reputation is built on the strength of our comprehensive preclinical platforms, spanning in vitro, in vivo, and ex vivo methodologies. Our capabilities combine established gold-standard approaches with proprietary LIDE technologies, ensuring every study delivers robust, clinically relevant data with efficiency in both time and cost.
We work closely with each client to design studies that align precisely with program goals, selecting the right models and methods to generate meaningful insights.
With over a decade dedicated exclusively to preclinical oncology, and a team of experienced PhD scientists, technicians, and bioinformaticians, LIDE supports your research from concept and study design through full execution. Every service can be performed as a stand-alone study or integrated into an end-to-end, IND-enabling program.

In Vivo Mouse Models
LIDE’s industry leading PDX and CDX library offers our clients access to unique, patient-consented, highly characterized, low-passage tumors for in vivo models.
· 2300+ patient derived xenograft (PDX) models
· 370+ naturally derived resistant models
· MiniPDX® 7 day in-vivo efficacy study
· 126 CDX models established and ready for use
Learn More ›

In Vitro and Ex Vivo Models
LIDE complements its in vivo expertise with a diverse suite of in vitro assays, providing scalable, mechanistic, and cost-effective platforms to support oncology drug discovery.
· Commercial cell lines for consistency of results
· Conditionally reprogrammed cells with matching PDX models
· Spheroids, organoids, many readily available for immediate studies
Learn More ›

Immuno Oncology Platform
LIDE offers a comprehensive suite of immuno-oncology models and assays to accelerate the development of checkpoint inhibitors, bispecific antibodies, cell therapies, ADCs, oncolytic viruses, and other IO agents.
· Murine and humanized syngeneic models for proof-of-concepts
· Donor-selected classic PBMC humanized models
· Novel HuPBMC/cancer co-inoculation model
· Effector engineered T/NK, Car-T, ADC and oncolytic virus
Learn More ›